Stockreport

Heron Therapeutics: Zynrelef Developments Are Unlikely To Provide Relief To Investors [Seeking Alpha]

Heron Therapeutics, Inc.  (HRTX) 
Last heron therapeutics, inc. earnings: 3/2 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: herontherapeutics.gcs-web.com/investor-home
PDF Follow Summary Zynrelef, a combination of bupivacaine and meloxicam, was FDA-approved in 2021 for postoperative pain management, offering a non-opioid alternative. [Read more]